2019-04-25T11:48:30-05:00 2018-12-31 050409384 KAHN LITWIN RENZA & CO LTD 951 NORTH MAIN STREET PROVIDENCE RI 02904 990 2018-01-01 522396428 ALZHEIMER'S DISEASE RESEARCH FOUNDATION D/B/A CURE ALZHEIMER'S FUND ALZH 7812373800 34 WASHINGTON ST NO 310 WELLESLEY HILLS MA 02481 TIMOTHY W ARMOUR PRESIDENT 7812373800 2019-04-22 1 DEBORAH A HOPKINS P00167843 4012742001 71.117.160.66 2019-04-22 07:36:31 ED P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 6C9B1A35775087DBDB8A6D25ECA509C7F6C27838 2018 2020-01-14 16:20:31Z X CURE ALZHEIMER'S FUND TIMOTHY W ARMOUR 34 WASHINGTON ST NO 310 WELLESLEY HILLS MA 02481 33301850 0 X WWW. CUREALZ.ORG X 2004 PA TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE THROUGH VENTURE BASED PHILANTHROPY WITH ALL ORGANIZATIONAL EXPENSES PAID BY THE BOARD, ALLOWING ALL PUBLIC CONTRIBUTIONS TO DIRECTLY FUND ALZHEIMER'S RESEARCH. 9 8 28 68 0 0 17501551 19798072 0 0 -7084 95723 3644 0 17498111 19893795 13884649 16744506 0 0 1321557 1766370 0 0 991061 3793348 5118435 18999554 23629311 -1501443 -3735516 10939018 7580826 530632 891589 10408386 6689237 TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE THROUGH VENTURE BASED PHILANTHROPY WITH ALL ORGANIZATIONAL EXPENSES PAID BY THE BOARD, ALLOWING ALL PUBLIC CONTRIBUTIONS TO DIRECTLY FUND ALZHEIMER'S RESEARCH. 0 0 19719704 16744506 IN 2018, CURE ALZHEIMER'S FUND SUPPORTED 74 RESEARCH PROJECTS AT 34 LEADING RESEARCH INSTITUTIONS, FOR A FUNDING TOTAL OF MORE THAN $19 MILLION. THE MAJORITY OF PROJECTS PURSUED A DEEPER UNDERSTANDING OF THE MECHANISMS OF ACTION OF THE GENES AND VARIANTS WITH THE BIGGEST IMPACT ON RISK AND TIMING OF ALZHEIMER'S DISEASE. OTHER PROJECTS PURSUED NOVEL THEORIES AND TOOLS TO ASSESS POTENTIAL AVENUES FOR PREVENTION AND TREATMENT. ADDITIONAL EXPENSES INCLUDE MODELS FROM AND TESTING BY CONTRACT ORGANIZATIONS; THE DIRECT SUPPORT OF FACILITATING GRANTS AND THEIR AWARD PROCESS; AND COSTS ASSOCIATED WITH HOSTING SCIENTIFIC MEETINGS. 2025654 CREATING AWARENESS TOOK THE FORM OF MAILINGS, OUTREACH, AND SUPPORT OF THIRD PARTY EVENTS DESIGNED TO RAISE AWARENESS ABOUT THE NEED OF MORE RESEARCH INTO THE ORIGINS AND PROGRESSION OF ALZHEIMER'S DISEASE. 25164 CURE ALZHEIMER'S FUND SERVES AS FIDUCIARY AGENT FOR A SERIES OF INDEPENDENTLY PRODUCED VIDEOS ABOUT ALZHEIMER'S DISEASE. WITH AN EXECUTIVE PRODUCER, THE ORGANIZATION RECEIVED FUNDS FROM THE METROPOLITAN LIFE FOUNDATION, DISPENSED THEM AS APPROVED BY THE EXECUTIVE PRODUCER AND REPORTED THE FINANCIAL ACTIVITY PERIODICALLY TO THE METROPOLITAN LIFE FOUNDATION. 21770522 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 36 0 28 1 0 0 0 0 0 0 0 0 0 0 0 0 X 9 8 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MA X X X TIMOTHY W ARMOUR 7812383800 34 WASHINGTON STREET STE 310 WELLESLEY HILLS MA 02481 JEFFREY MORBY CO-CHAIRMAN 20.00 X X 0 0 0 HENRY MCCANCE CO-CHAIRMAN 5.00 X X 0 0 0 TIMOTHY ARMOUR PRESIDENT & CEO 40.00 X X 249827 0 7927 PHYLLIS RAPPAPORT TREASURER 2.00 X X 0 0 0 MARGARET SMITH SECRETARY & SR VP 20.00 X 124385 0 3768 BILL BENTER DIRECTOR (AS OF 4/18) 2.00 X 0 0 0 ROBERT GREENHILL DIRECTOR 2.00 X 0 0 0 JAY JESTER DIRECTOR 5.00 X 0 0 0 JACQUELINE MORBY DIRECTOR 5.00 X 0 0 0 SHERRY SHARP DIRECTOR 2.00 X 0 0 0 BARBARA CHAMBERS SENIOR VICE PRESIDENT 40.00 X 166450 0 15030 SALLY G ROSENFIELD SENIOR VICE PRESIDENT 40.00 X 169903 0 15366 JOHN SLATTERY SENIOR VICE PRESIDENT 40.00 X 173623 0 5315 LAUREL LYLE VICE PRESIDENT 40.00 X 58940 0 1844 943128 0 49250 5 0 1 0 GRYPHON CONSULTING INC 21 DEAN ST BELMONT MA 02478 FINANCIAL & MGT CONSULTANT 179457 PROPER VILLIANS INC 668 STONY HILL RD YARDLEY MA 19067 CREATIVE SERVICES 168005 CHOATE HALL & STEWART TWO INTERNATIONAL PLACE BOSTON MA 02110 LEGAL FEES 120487 3 19798072 4223565 19798072 77320 77320 13407803 18655 13374952 33103 32851 -14448 18403 18403 19893795 0 0 95723 15720439 15720439 1024067 1024067 992378 575579 188552 228247 606216 351606 115181 139429 15506 8993 2947 3566 41938 24324 7968 9646 110332 63993 20963 25376 166139 105751 6771 53617 167837 167837 102424 102424 18103 18103 622664 428286 98739 95639 76913 66793 10120 355038 96728 69343 188967 77583 15986 61597 154681 89715 29390 35576 217693 139550 37729 40414 505404 357528 5765 142111 16622 16622 6968 1589 5379 RESEARCH LAB EXPENSES 2541211 2541211 MISCELLANEOUS 63991 30796 14842 18353 DOCUMENTARY PROGRAM PRO 25164 25164 23629311 21770522 867728 991061 4096006 2352595 179386 148396 785013 2437328 183265 259681 54458 16107 42857 38351 3990040 3996790 10136 0 10939018 7580826 319678 392536 210954 499053 530632 891589 X 8303832 5466208 2104554 1223029 10408386 6689237 10939018 7580826 -3735516 16367 0 X 0 1 X 1 0 X 12640759 11248214 16220862 17501551 19798072 77409458 12640759 11248214 16220862 17501551 19798072 77409458 10304966 67104492 383 764 611 13021 77320 92099 3150 90 3644 6884 77508441 0.86580 0.83870 X 0 0 0 0 0 0 1 102424 0 0 102424 0 PART II-B, LINE 1(G) A REGISTERED LOBBYIST CONTACTED VARIOUS CONGRESSIONAL LEGISLATORS FOR THE PURPOSE OF ENCOURAGING INCREASED FUNDING OF ALZHEIMER'S DISEASE RESEARCH BY THE FEDERAL GOVERNMENT. 54458 16107 38351 38351 ACCRUED EXPENSE 499053 499053 X 19910162 16367 16367 19893795 0 19893795 23629311 0 23629311 0 23629311 PART X, LINE 2: THE ORGANIZATION IS EXEMPT FROM INCOME TAXES AS A PUBLIC CHARITY UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. MANAGEMENT BELIEVES THAT THE ORGANIZATION OPERATES IN A MANNER CONSISTENT WITH ITS TAX-EXEMPT STATUS AT BOTH THE STATE AND FEDERAL LEVEL. THE ORGANIZATION ANNUALY FILES IRS FORM 990- RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX REPORTING VARIOUS INFORMATION THAT THE IRS USES TO MONITOR THE ACTIVITIES OF TAX-EXEMPT ENTITIES. THESE TAX RETURNS ARE SUBJECT TO REVIEW BY THE TAXING AUTHORITIES, GENERALLY FOR A PERIOD OF THREE YEARS AFTER THEY WERE FILED. THE ORGANIZATION CURRENTLY HAS NO TAX EXAMINATIONS IN PROGESS. 0 EAST ASIA AND THE PACIFIC 0 0 GRANTS AWARDED ALZHEIMER'S DISEASE RESEARCH 150000 NORTH AMERICA 0 0 GRANTS AWARDED ALZHEIMER'S DISEASE RESEARCH 251379 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTS AWARDED ALZHEIMER'S DISEASE RESEARCH 622688 0 0 0 0 0 0 1024067 0 1024067 EAST ASIA AND THE PACIFIC SYNAPSE PRUNING BY ASTROCYTES: A POTENTIAL NEW TARGET FOR TREATING ALZHEIMER'S DISEASE 150000 CHECK NORTH AMERICA USING HUMAN BIOENGINEERED CEREBRAL VESSELS TO EXPLORE HOW NATIVE APOLIPOPROTEIN E AFFECTS CEREBROVASCULAR PROPERTIES RELEVANT TO AD 251379 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) EPIGENETIC DETERMINANTS OF HUMAN COGNITIVE AGING 199600 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) REVERSAL OF TAU PATHOLOGY BY AN ADENOSINE A1 RECEPTOR ANTAGONIST 287500 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) ABETA MEDIATED INHIBITION OF GAMMA-SECRETASE ACTIVITY INDUCES AD RELEVANT CELLULAR PHENOTYPES 135588 CHECK 5 0 0 0 0 0 0 PART I LINE 2 THE RESEARCH LEADERSHIP GROUP REVIEWS EACH PROPOSAL FOR FIT WITH THE CURE ALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S DISEASE. ALL FUNDED RESEARCHERS MAY BE ASKED TO REVIEW OCCASIONAL PROPOSALS ON A THREE-WEEK TIMELINE AS A CONDITION OF RECEIVING FUNDING. THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT PROPOSAL FITS WITHIN THE ORGANIZATION'S MISSION TO FUND RESEARCH CONTRIBUTING TO A CURE FOR ALZHEIMER'S DISEASE. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY REVIEWER MAY RESULT IN A REQUEST FOR ITERATION OR REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTIONS, OR REJECTION BUT WILL NOT RECEIVE ANY "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION IF A PROPOSAL IS FUNDED. 1 BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON MA 02215 042103881 501 (C)(3) 209725 UTILIZING FUNCTIONAL MAPS TO PRIORITIZE THERAPEUTIC TARGETS IN AD BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02115 042312909 501 (C)(3) 250000 THE ROLE OF APOE IN MICROGLIA REGULATION IN NEURODEGENERATION CARNEGIE MELLON UNIVERSITY 4400 FIFTH AVE PITTSBURGH PA 15213 250969449 501 (C)(3) 198021 CIRCUITS: INTERPRETING ALZHEIMER'S DISEASE-ASSOCIATED GENETIC VARIATION AT ENHANGER REGION BOSTON CHILDRENS HOSPITAL 300 LONGWOOD AVE BOSTON MA 02115 042774441 501 (C)(3) 149999 TEMPORAL ANALYSIS OF INFECTION IN ALZHEIMER'S DISEASE MODELS BOSTON CHILDRENS HOSPITAL 300 LONGWOOD AVE BOSTON MA 02115 042774441 501 (C)(3) 299924 MICROGLIAL HETEROGENEITY AND TRANSCRIPTIONAL STATE CHANGES IN ALZHEIMER'S DISEASE COLUMBIA UNIVERSITY 710 WEST 168TH STREET 3RD FLOOR NEW YORK NY 10032 135598093 501 (C)(3) 150000 NOVEL CHEMICAL MODULATION FOR BRACE 1-MEDIATED CLEAVAGE OF B-AMYLOID PRECURSOR PROTEIN HARVARD COLLEGE 677 HUNTINGTON AVE BOSTON MA 02115 042103580 501 (C)(3) 250000 ASSESSING THE LINKS BETWEEN THE MS4A RISK GENESE, MICROGLIA, AND ALZHEIMER'S DISEASE HARVARD COLLEGE 677 HUNTINGTON AVE BOSTON MA 02115 042103580 501 (C)(3) 250000 ANALYTICAL AND STATISTICAL TOOLS FOR SEQUENCE ANALYSIS FOR ALZHEIMER'S DISEASE HARVARD COLLEGE 677 HUNTINGTON AVE BOSTON MA 02115 042103580 501 (C)(3) 172500 ACTIVATION OF THE 26S PROTEASOME FOR THE TREATMENT OF ALZHEIMER'S DISEASE HOUSTON METHODIST HOSPITAL FOUNDATION PO BOX 4384 HOUSTON TX 77210 760094743 501 (C)(3) 287500 UNCOVERING THE MOLECULAR MECHANISM OF SELECTED DRUG CANDIDATES DERIVED FROM SYSTEMATIC ALZHEIMER'S DRUG REPOSITIONING MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 172500 IMAGING MICROGLIAL HOMEOSTASIS AND DISRUPTION P2RY12 RADIOTRACER DEVELOPMENT MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 287500 ROLE OF ATXN1 IN REGULATING BACE1 ACTIVITY MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 172500 THE ROLE OF NEUREXINS IN ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 100000 NEUROIMMUNE MOLECULAR IMAGING: REDEFINING THE LANDSCAPE OF OPPORTUNITIES IN AD MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 300000 UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 148732 CIRCUITS: IPS CELLS AND THE HUMAN BRAINS MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 170907 EFFECTS OF CEREBROVASCULAR INSUFFICIENCY AND EXERCISE ON THE ALZHEIMER'S BRAIN MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 172500 INHIBITING CD33 FUNCTION AND MODULATING MICROGLIAL ACTIVATION STATE FOR ALZHEIMER'S DISEASE THERAPY MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 143750 INDENTIFYING BLOOD-BRAIN BARRIER ENHANCERS AND ROLE OF NEUTROPHILS IN A 3D BBB VASCULARIZED MODEL OF ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 172500 THE IMPACT OF AD-ASSOCIATED GENETIC VARIANTS IN 3D HUMAN MIXED NEURALGLIAL MODELS OF AD MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 345000 HIGH THROUGH PUT DRUG SCREENING FOR AD USING 3D HUMAN NEURAL CULTURE SYSTEMS MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 193890 GENES TO THERAPIES CENTRALIZED RESEARCH CORE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 345000 NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN AD MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 171932 INTERLEUKIN-3 IN AD MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 1725000 ALZHEIMER'S GENOME PROJECT MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVE CAMBRIDGE MA 02139 042103594 501 (C)(3) 460000 FUNCTIONAL ANALYSIS OF AD RISK GENES USING HUMAN INDUCED PLURIPOTENT STEM CELLS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVE CAMBRIDGE MA 02139 042103594 501 (C)(3) 125000 IDENTIFYING BLOOD-BRAIN BARRIER ENHANCERS AND ROLE OF NEUTROPHILS IN A BB VASCULARIZED MODEL OF ALZHEIMER'S DISEASE MAYO CLINIC 200 FIRST ST SW ROCHESTER MN 55905 416011702 501 (C)(3) 172500 SENESCENT CELLS AND ALZHEIMER'S DISEASE MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD S JACKSONVILLE FL 32224 593337028 501 (C)(3) 250000 APOE: BU YEAR 2 NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 1ST AVE R607 NEW YORK NY 10016 501 (C)(3) 250000 NEUROTOXIC REACTIVE ASTROCYES IN ALZHEIMER'S DISEASE NORTHWESTERN UNIVERSITY 633 CLARK STREET EVANSTON IL 60208 362167817 501 (C)(3) 172500 THE ROLE OF IMPAIRED SYNAPTIC VESICLE MACHINERY PROTEOSTATSIS IN ALZHEIMER'S DISEASE PATHOGENESIS PALO ALTO VETERANS INSTITUTE FOR RESEARCH 3801 MIRANDA AVE 101-A2-210 PALO ALTO CA 94304 770207331 501 (C)(3) 172500 REJUVENATION OF MICROGLIA IN BRAIN AGING AND NEURODEGENERATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 1111 FRANKLIN ST 12TH FLOOR OAKLAND CA 94607 943067788 501 (C)(3) 250000 INTERPRETATION OF NON-CODING RISK ALLELES OF AD THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 1111 FRANKLIN ST 12TH FLOOR OAKLAND CA 94607 943067788 501 (C)(3) 172500 HUMAN-SPECIFIC EVOLUTION OF CD33: EVOLUTIONARY RELATIONSHIP TO ANCIENT HOST-PATHOGEN INTERACTIONS AND CURRENT IMPLICATION FOR ALZHEIMER'S DISEASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 1111 FRANKLIN ST 12TH FLOOR OAKLAND CA 94607 943067788 501 (C)(3) 100479 ABETA MEDIATED INHIBITION OF GAMMA-SECRETASE ACTIVITY INDUCES AD-RELEVANT CELLULAR PHENOTYPES MOBLEY THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 131624158 501 (C)(3) 250000 IMPACT OF APOE AND SEX ON VULNERABLE NEURON-SPECIFIC FUNCTIONAL NETWORKS THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 131624158 501 (C)(3) 517500 DISCOVERY OF CHEMICAL COMPOUNDS THAT INDUCE DEGRADATION OF APP-B-CTF IN CELLS THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 131624158 501 (C)(3) 150000 STRICKLAND NORRIS YEAR 2: THE ROLE OF THE CONTACT SYSTEM IN AD THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 131624158 501 (C)(3) 172500 YEAR 1: THE DEVELOPMENT OF DNA-ENCODED LIBRARIES TO DISCOVER THERAPEUTICALLY VALUABLE LOW MOLECULAR WEIGHT COMPOUNDS FOR AD THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 10010 N TORREY PINES ROAD LA JOLLA CA 92037 952160097 501 (C)(3) 109250 WHOLE GENOME CHARACTERIZATION OF DNA METHYLATION CHANGES IN THE AGED AND AD THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 10010 N TORREY PINES ROAD LA JOLLA CA 92037 952160097 501 (C)(3) 150000 MICROGLIAL TAM RECEPTORS AS MODULATORS OF AD THE TRUSTEES OF BOSTON UNIVERSITY 25 BUICK STREET BOSTON MA 02115 042103547 501 (C)(3) 172500 EVALUATION OF THE EFFECT OF CELL TYPE- SPECIFIC DELETION OF ESCRT GENES ON THE SPREAD OF TAU PATHOLOGY THE TRUSTEES OF BOSTON UNIVERSITY 25 BUICK STREET BOSTON MA 02115 042103547 501 (C)(3) 172500 AD PHARMACOMICS IN 3D THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN RIVE LA JOLLA CA 92093 501 (C)(3) 172500 IDENTIYING THE BLOOD BRAIN BARRIER CHANGES DURING AD THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN RIVE LA JOLLA CA 92093 501 (C)(3) 373750 PHARMACOLOGICALLY PROTECTING AND RESCUING SYNAPSES FROM BETA AMYLOID BY RAISING SYNAPTIC PSD-95 HEAD THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN RIVE LA JOLLA CA 92093 501 (C)(3) 287500 AD RELATED MUTATIONS IN PROTEIN KINASE C THE TRUSTEES OF TUFTS COLLEGE 419 BOSTON AVE MEDFORD MA 02115 501 (C)(3) 150000 FUNCTIONAL CHARACTERIZATION OF GGA3 MUTATIONS ASSOCIATED WITH AD UNIVERSITY OF CONNECTICUT HEALTH CENTER 263 FARMINGTON AVE FARMINGTON CT 06030 501 (C)(3) 172500 PHYSIOLOGICAL METHOD FOR EARLY DETECTION OF SYNAPTIC VULNERABILITY IN AD MODEL ANIMALS UNIVERSITY OF MICHIGAN 500 S STATE ST ANN ARBOR MI 48109 501 (C)(3) 241738 2018 PAULSON GIORDANI HAMPSTEAD UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE 9201 UNIVERSITY CITY BLVD CHARLOTTE NC 28223 501 (C)(3) 200000 STUDY OF REACTIVE ASTROCYTES DERIVED OXIDATIVE STRESS AND MICROGLIAL NEURODEGENERATIVE INFLAMMATION IN AD UNIVERSITY OF SOUTHERN CALIFORNIA UNIVERSITY PARK LOS ANGELES CA 90089 951642394 501 (C)(3) 300000 PICALM GENE THERAPY AND DRUG SCREENING FOR AMYLOID BETA CLEARANCE UNIVERSITY OF SOUTHERN CALIFORNIA UNIVERSITY PARK LOS ANGELES CA 90089 951642394 501 (C)(3) 172500 TARGETING BENEFICIAL INNATE IMMUNITY IN AD BY IRAK-M DELETION UNIVERSITY OF SOUTHERN CALIFORNIA UNIVERSITY PARK LOS ANGELES CA 90089 951642394 501 (C)(3) 345000 THE ROLE OF PICALM MUTATIONS IN AD UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 752556007 501 (C)(3) 172500 GENETIC TARGETS TO BLOCK TAU PROPAGATION: TEST KNOCKDOWN OF HSPG GENES IN VIVO UNIVERSITY OF VIRGINIA 21 UNIVERSITY CIRCLE CHARLOTTESVILLE VA 22903 501 (C)(3) 230000 MENINGEAL LYMPHATIC FUNCTION AND ANTIBODY THERAPY IN AD UNIVERSITY OF VIRGINIA 21 UNIVERSITY CIRCLE CHARLOTTESVILLE VA 22903 501 (C)(3) 230000 CELL CYCLE RE-ENTRY IN 3D HUMAN NEURON CULTURES WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 501 (C)(3) 79594 SCIENTIFIC DIRECTIONS FOR THE EXPLORATIONS OF RACIAL DISPARITIES IN AD WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 501 (C)(3) 172500 MODELING AD IN SPECIFIC SUBTYPES OF HUMAN NEURONS THROUGH THE DIRECT NEURONAL REPROGRAMMING WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 501 (C)(3) 300000 UNDERSTANDING THE EFFECT OF APOE ON TAU-MEDIATED NEURODENERATION WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 501 (C)(3) 250000 APOE PROTEOFORMS IN HUMAN CNS AND VALIDATION OF TRANSLATIONAL APOE PHARMACODYNAMIC MARKERS WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 501 (C)(3) 172500 CENTRAL CLOCK INFLUENCE ON ALZHEIMER'S DISEASE PATHOGENESIS WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 501 (C)(3) 172137 THE CIRCADIAN CLOCK MODULATES NEURODENERATION IN AD VIA REVE-ERB WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1167 YORK AVE NEW YORK NY 10065 501 (C)(3) 170861 AD RISK IS HIGHER IN WOMEN: IDENTIFICATION OF FEMALE SPECIFIC BRAIN BIOENERGETIC TARGETS WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1167 YORK AVE NEW YORK NY 10065 501 (C)(3) 172500 DIETARY SALT TAU PHOSPHRYLATION AND COGNITIVE IMPAIRMENT WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 9 CAMBRIDGE CENTER CAMBRIDGE MA 02142 061043412 501 (C)(3) 178250 WHOLE GENOME CHARACTERIZATION OF DNA METHYLATION CHANGES IN THE AGED AND AD YALE UNIVERSITY 333 CEDAR ST NEW HAVEN CT 06510 060646973 501 (C)(3) 172500 ROLE OF MICROGLIAL PROTEIN SPARC IN CONTROL OF INFLAMMASOME ACTIVATION YALE UNIVERSITY 333 CEDAR ST NEW HAVEN CT 06510 060646973 501 (C)(3) 172500 THE NEUROPROTECTIVE GLIAL BARRIER: A MULTICELLULAR REACTION WITH THERAPEUTIC POTENTIAL IN AD 30 PART I, LINE 2: THE RESEARCH LEADERSHIP GROUP REVIEWS EACH PROPOSAL FOR FIT WITH THE CURE ALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S DISEASE. ALL FUNDED RESEARCHERS MAY BE ASKED TO REVIEW OCCASIONAL PROPOSALS ON A THREE-WEEK TIMELINE AS A CONDITION OF RECEIVING FUNDING. THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT PROPOSAL FITS WITHIN THE ORGANIZATION'S MISSION TO FUND RESEARCH CONTRIBUTING TO A CURE FOR ALZHEIMER'S DISEASE. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY REVIEWER MAY RESULT IN A REQUEST FOR ITERATION OR REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTIONS, OR REJECTION BUT WILL NOT RECEIVE ANY "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION IF A PROPOSAL IS FUNDED. X X X X 0 0 0 0 0 0 0 0 0 TIMOTHY ARMOUR PRESIDENT & CEO 249827 0 0 0 0 0 7927 0 0 0 257754 0 0 0 BARBARA CHAMBERS SENIOR VICE PRESIDENT 166450 0 0 0 0 0 5290 0 9740 0 181480 0 0 0 SALLY G ROSENFIELD SENIOR VICE PRESIDENT 169903 0 0 0 0 0 5634 0 9732 0 185269 0 0 0 JOHN SLATTERY SENIOR VICE PRESIDENT 173623 0 0 0 0 0 5315 0 0 0 178938 0 0 0 X 80 4223565 SALE PRICE 0 0 0 1 PART I, LINE 32B: WHEN STOCK IS RECEIVED AS A CONTRIBUTION IT IS SOLD IMMEDIATELY UPON RECEIPT OR SOON THEREAFTER AS IS PRACTICAL THROUGH BANK OF NEW YORK/MELLON. FORM 990, PART VI, SECTION A, LINE 2 JEFFREY MORBY AND JACQUELINE MORBY ARE BOTH DIRECTORS AND SPOUSES. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY THE EXTERNAL AUDITORS AND REVIEWED BY THE PRESIDENT AND CONTRACT CFO. REVISIONS, CORRECTIONS, ETC. ARE MADE AS NECESSARY. ONCE ALL ARE SATISFIED WITH THE FORM, IT IS FINALIZED AND A COPY IS SENT TO ALL BOARD MEMBERS. FORM 990, PART VI, SECTION B, LINE 12C EACH YEAR THE ORGANIZATION'S CONFLICT OF INTEREST POLICY IS PROVIDED TO ALL OFFICERS, DIRECTORS AND KEY EMPLOYEES. THESE PEOPLE ARE ASKED TO REVIEW THE POLICY AND SIGN A STATEMENT INDICATING THAT THEY UNDERSTAND THE POLICY AND HAVE REPORTED ALL POTENTIAL CONFLICTS DURING THE PAST YEAR IN ACCORDANCE WITH THE POLICY AND WILL REPORT ALL POTENTIAL CONFLICTS DURING THE COMING YEAR. ALL POTENTIAL CONFLICTS ARE EVALUATED BY THE BOARD TO DETERMINE IF A CONFLICT ACTUALLY EXISTS. IN THOSE INSTANCES WHERE THE POTENTIAL TRANSACTION IS A CONFLICT, THE BOARD EXAMINES THE TRANSACTION AND A VOTE IS TAKEN (WITH THOSE INVOLVED RECUSING THEMSELVES) AS TO WHETHER THE ORGANIZATION WILL ENTER INTO THE TRANSACTION. FORM 990, PART VI, SECTION B, LINE 15 COMPARABILITY DATA IS SUBMITTED ANNUALLY TO THE EXECUTIVE COMMITTEE FOR COMPENSATION APPROVAL FOR THE PRESIDENT AND ALL OTHER EMPLOYERS. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. THE ORGANIZATION'S FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST AND AT THE ORGANIZATION'S WEBSITE.